The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Open accessAbstract
SUMMARY Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective and orally-bioavailable small molecule inhibitor VTP50469. Cell lines carrying MLL-rearrangements were selectively responsive to VTP50469. VTP50469 displaced Menin from protein complexes and inhibited chromatin occupancy of MLL at select genes. Loss of MLL binding led to changes in gene expression, differentiation, and apoptosis. Patient-derived xenograft (PDX) models derived from patients with either MLL-r AML or MLL-r ALL showed dramatic reductions of leukemia burden when treated with VTP50469. Multiple mice engrafted with MLL-r ALL remained disease free greater than one year after treatment. These data support rapid translation of this approach to clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Full-length RNA-seq from single cells using Smart-seq2
Picelli, S., Faridani, O. R., Björklund, Å. K., Winberg, G., Sagasser, S., & Sandberg, R. (2014) · Nature Protocols · doi:10.1038/nprot.2014.006 · Cited by 4,137
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites
Skene, P. J., & Henikoff, S. (2017) · eLife · doi:10.7554/elife.21856 · Cited by 1,776
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
Self-citationRational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation
Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.3026 · Cited by 1,617
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513
Self-citationMLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Self-citationVariant Review with the Integrative Genomics Viewer
Robinson, J. T., Thorvaldsdóttir, H., Wenger, A. M., Zehir, A., & Mesirov, J. P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0337 · Cited by 1,115
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Self-citationhDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
The MLL recombinome of acute leukemias in 2017
Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-de-Oliveira, M. S., et al. (2018) · Leukemia · doi:10.1038/leu.2017.213 · Cited by 676
Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
Yokoyama, A., & Cleary, M. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.003 · Cited by 555
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.001 · Cited by 550
Self-citationMenin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 462
CEAS: cis-regulatory element annotation system
Shin, H., Liu, T., Manrai, A. K., & Liu, X. S. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp479 · Cited by 461
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.016 · Cited by 392
The super elongation complex (SEC) and MLL in development and disease
Smith, E., Lin, C., & Shilatifard, A. (2011) · Genes & Development · doi:10.1101/gad.2015411 · Cited by 361
The molecular biology of mixed lineage leukemia
Slany, R. K. (2009) · Haematologica · doi:10.3324/haematol.2008.002436 · Cited by 321
Unique and Independent Roles for MLL in Adult Hematopoietic Stem Cells and Progenitors
Jude, C. D., Climer, L., Xu, D., Artinger, E., Fisher, J. K., & Ernst, P. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.019 · Cited by 319
Bitoun, E., Oliver, P. L., & Davies, K. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl444 · Cited by 312
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia
Guenther, M. G., Lawton, L. N., Rozovskaia, T., Frampton, G. M., Levine, S. S., Volkert, T. L., Croce, C. M., Nakamura, T., Canaani, E., & Young, R. A. (2008) · Genes & Development · doi:10.1101/gad.1741408 · Cited by 270
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Kühn, M. W. M., Song, E., Feng, Z., Sinha, A., Chen, C.-W., Deshpande, A. J., Cusan, M., Farnoud, N., Mupo, A., Grove, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0237 · Cited by 264
Self-citationLiem, N. L. M., Papa, R. A., Milross, C. G., Schmid, M. A., Tajbakhsh, M., Choi, S., Ramirez, C. D., Rice, A. M., Haber, M., Norris, M. D., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2911 · Cited by 238
Self-citationMultiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in Leukemogenesis
Milne, T. A., Kim, J., Wang, G. G., Stadler, S. C., Basrur, V., Whitcomb, S. J., Wang, Z., Ruthenburg, A. J., Elenitoba-Johnson, K. S. J., Roeder, R. G., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.011 · Cited by 230
Chen, C.-W., Koche, R. P., Sinha, A. U., Deshpande, A. J., Zhu, N., Eng, R., Doench, J. G., Xu, H., Chu, S. H., Qi, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3832 · Cited by 228
Self-citationDeguchi, K., Ayton, P. M., Carapeti, M., Kutok, J. L., Snyder, C. S., Williams, I. R., Cross, N. C. P., Glass, C. K., Cleary, M. L., & Gilliland, D. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00051-5 · Cited by 225
Lock, R. B., Liem, N., Farnsworth, M. L., Milross, C. G., Xue, C., Tajbakhsh, M., Haber, M., Norris, M. D., Marshall, G. M., & Rice, A. M. (2002) · Blood · doi:10.1182/blood.v99.11.4100 · Cited by 208
Self-citationShi, A., Murai, M. J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., & Cierpicki, T. (2012) · Blood · doi:10.1182/blood-2012-05-429274 · Cited by 204
Milne, T. A., Martin, M. E., Brock, H. W., Slany, R. K., & Hess, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1041 · Cited by 182
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
Self-citationSeparation and parallel sequencing of the genomes and transcriptomes of single cells using G&T-seq
Macaulay, I. C., Teng, M. J., Haerty, W., Kumar, P., Ponting, C. P., & Voet, T. (2016) · Nature Protocols · doi:10.1038/nprot.2016.138 · Cited by 170
Wang, Q., Wu, G. Y., Mi, S., He, F., Wu, J., Dong, J., Luo, R. T., Mattison, R. J., Kaberlein, J. J., Prabhakar, S., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324699 · Cited by 139
CUT&RUNTools: a flexible pipeline for CUT&RUN processing and footprint analysis
Zhu, Q., Liu, N., Orkin, S. H., & Yuan, G. (2019) · Genome biology · doi:10.1186/s13059-019-1802-4 · Cited by 139
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Dafflon, C., Craig, V. J., Méreau, H., Gräsel, J., Engstler, B. S., Hoffman, G., Nigsch, F., Gaulis, S., Barys, L., Ito, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.327 · Cited by 126
Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia
Liang, K., Volk, A. G., Haug, J. S., Marshall, S. A., Woodfin, A. R., Bartom, E. T., Gilmore, J. M., Florens, L. A., Washburn, M. P., Sullivan, K. D., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.011 · Cited by 123
A role for MEIS1 in MLL-fusion gene leukemia
Kumar, A. R., Li, Q., Hudson, W. A., Chen, W., Sam, T. N., Yao, Q., Lund, E. A., Wu, B., Kowal, B. J., & Kersey, J. H. (2008) · Blood · doi:10.1182/blood-2008-06-163287 · Cited by 96
MLL-AF9– and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C
Zhu, N., Chen, M., Eng, R., DeJong, J., Sinha, A. U., Rahnamay, N. F., Koche, R. P., Al‐Shahrour, F., Minehart, J. C., Chen, C.-W. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82978 · Cited by 89
Self-citationMEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Brown, F. C., Still, E., Koche, R. P., Yim, C. Y., Takao, S., Cifani, P., Reed, C., Gunasekera, S., Ficarro, S. B., Romanienko, P. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1271 · Cited by 85
Self-citationFAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis
Rani, N., Aichem, A., Schmidtke, G., Kreft, S. G., & Groettrup, M. (2012) · Nature Communications · doi:10.1038/ncomms1752 · Cited by 83
Kerry, J., Godfrey, L., Repapi, E., Tapia, M. C., Blackledge, N. P., Ma, H., Ballabio, E., O’Byrne, S., Ponthan, F., Heidenreich, O. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.054 · Cited by 79
Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia
Okuda, H., Stanojević, B., Kanai, A., Kawamura, T., Takahashi, S., Matsui, H., Takaori‐Kondo, A., & Yokoyama, A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91406 · Cited by 76
Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls
Charles, N. J., & Boyer, D. F. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0218-ra · Cited by 72
Orlovsky, K., Kalinkovich, A., Rozovskaia, T., Shezen, E., Itkin, T., Alder, H., Özer, H. G., Carramusa, L., Avigdor, A., Volinia, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103154108 · Cited by 69
Mixed-Lineage Leukemia Fusions and Chromatin in LeukemiaPreprint
Krivtsov, A. V., Hoshii, T., & Armstrong, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026658 · Cited by 66
Self-citationChromatin modifications as therapeutic targets in MLL-rearranged leukemia
Deshpande, A. J., Bradner, J. E., & Armstrong, S. A. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.06.002 · Cited by 63
Self-citationRichmond, J., Carol, H., Evans, K., High, L. M., Mendomo, A., Robbins, A. K., Meyer, C., Venn, N. C., Marschalek, R., Henderson, M. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2300 · Cited by 61
Self-citationJones, L., Carol, H., Evans, K., Richmond, J., Houghton, P. J., Smith, M. A., & Lock, R. B. (2016) · Leukemia · doi:10.1038/leu.2016.192 · Cited by 54
Self-citationPBX3 is essential for leukemia stem cell maintenance in MLL‐rearranged leukemia
Guo, H.-D., Chu, Y., Wang, L., Chen, X., Chen, Y., Cheng, H., Zhang, L., Zhou, Y., Yang, F.-C., Cheng, T., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30739 · Cited by 47
MLL Leukemia and Future Treatment Strategies
Marschalek, R. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400449 · Cited by 39
Xu, Y., Yue, L., Wang, Y., Xing, J., Chen, Z., Shi, Z., Liu, R., Liu, J. Y.-C., Luo, X., Jiang, H., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00185 · Cited by 26
Structure-based Design Technology C ONTOUR and its Application to Drug Discovery
Liu, Z., Lindblom, P., Claremon, D. A., & Singh, S. B. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735056-00265 · Cited by 5
Self-citation
Cited by
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Issa, G. C., Aldoss, I., DiPersio, J., Cuglievan, B., Stone, R., Arellano, M., Thirman, M. J., Patel, M. R., Dickens, D. S., Shenoy, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05812-3 · Cited by 507
Self-citationEpigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 493
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Recent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., et al. (2020) · Science · doi:10.1126/science.aax5863 · Cited by 257
Self-citation
Metadata
- Authors
- Krivtsov, A. V., Evans, K., Gadrey, J. Y., Eschle, B. K., Hatton, C., Uckelmann, H. J., Ross, K. N., Perner, F., Olsen, S. N., Pritchard, T., McDermott, L., Jones, C. D., Jing, D., Braytee, A., Chacon, D., Earley, E., McKeever, B. M., Claremon, D., Gifford, A. J., Lee, H. J., Teicher, B. A., Pimanda, J. E., Beck, D., Perry, J. A., Smith, M. A., McGeehan, G. M., Lock, R. B., & Armstrong, S. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 36
- Issue
- 6
- Pages
- 660-673.e11
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2993435749
- Cited by
- 447
- References
- 66
- FWCI
- 25.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.